Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:626797.
doi: 10.1155/2014/626797. Epub 2014 Jun 12.

Pharmacovigilance and moroccan tuberculosis public program: current situation

Affiliations

Pharmacovigilance and moroccan tuberculosis public program: current situation

Driss Soussi Tanani et al. Tuberc Res Treat. 2014.

Abstract

The objective of this work is to demonstrate the interest of integration of pharmacovigilance in Moroccan Tuberculosis Control Program (MTCP). Design and Data Collection. The integration of pharmacovigilance in MTCP was conducted in October 2012 with the Global Fund support. We compared the reports notified before and after this integration (period 1: January 2010-October 2012; period 2: October 2012-December 2013). The detection of signals was based on the Information Component available in VigiMine. We used the SPSS version 10.0 and MedCalc version 7.3 for data analysis. Results. The average number of spontaneous reports increased from 3.6 to 37.4 cases/month (P < 10(-3)). The average age was 40.7 ± 17.5 years; the sex ratio was 0.8. Hepatic reactions (32.7%) predominated during the first period, while skin reactions (24.1%) were in the second period (P = 10(-4)), and 40.9% of cases in the first period were serious against 15.8% in second period (P = 0.003). Nine signals were generated (hepatic enzyme increase, cholestasis, jaundice, arthralgia, acne, lower limb edema, pruritus, skin rashes, and vomiting). Conclusion. The integration of pharmacovigilance in Moroccan Tuberculosis Control Program improved the management of ADRs and detected new signals of antituberculosis drugs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of average times to onset of cutaneous, hepatic, and neurological ADRs.

References

    1. Perriot J, Chambonnet É, Eschalier A. Les effets indésirables des antituberculeux; prise en charge. Revue des Maladies Respiratoires. 2011;28(4):542–555. - PubMed
    1. Bloss E, Kukša L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. International Journal of Tuberculosis and Lung Disease. 2010;14(3):275–281. - PubMed
    1. Awofeso N. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bulletin of the World Health Organization. 2008;86(3):B–D. - PMC - PubMed
    1. Berg J, Blumberg EJ, Sipan CL, et al. Somatic complaints and isoniazid (INH) side effects in Latino adolescents with latent tuberculosis infection (LTBI) Patient Education and Counseling. 2004;52(1):31–39. - PubMed
    1. http://srvweb.sante.gov.ma/Documents/BE%20edition%20complet.pdf.

LinkOut - more resources